SCHEMBL8490451

SCHEMBL8490451

Cc1cc(CO)cnc1F

nearest known ligand 0.38

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CYP2A6 P11509 1/20 0.38
SHBG P04278 1/20 0.34
GPR52 Q9Y2T5 1/20 0.33
HSD17B10 Q99714 1/20 0.33
FYN P06241 1/20 0.33
AGBL2 Q5U5Z8 1/20 0.33
PTGS1 P23219 1/20 0.32
PTGS2 P35354 1/20 0.32
RECQL P46063 1/20 0.31
CHRM4 P08173 1/20 0.31
CYP11B1 P15538 1/20 0.31
CYP11B2 P19099 1/20 0.31
PIK3R1 P27986 1/20 0.31
PIK3CA P42336 1/20 0.31
ABL1 P00519 3/20 0.31
MMP13 P45452 1/20 0.30
NPC1 O15118 1/20 0.30
POLB P06746 1/20 0.30
RAB9A P51151 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9970964 0.81 NOS3 (0.35) GPR52AGBL2NPC1RAB9A
SCHEMBL28762215 0.79 GPR52 (0.31) GPR52AGBL2
SCHEMBL21278154 0.79 LOXL2 (0.39) GPR52CHRM4
SCHEMBL29738505 0.79 GPR52 (0.31) GPR52AGBL2
SCHEMBL336161 0.78 SHBG (0.41) CYP2A6SHBGHSD17B10FYNRECQL
SCHEMBL16619402 0.76 SLC6A4 (0.36) CYP2A6GPR52CHRM4MMP13
SCHEMBL335548 0.76 AGBL2 (0.37) CYP2A6SHBGHSD17B10FYNAGBL2
SCHEMBL17229282 0.76 S1PR1 (0.33) GPR52POLB
SCHEMBL14667129 0.76 ESR1 (0.32) GPR52
SCHEMBL16629768 0.76 PTGS1 (0.34) GPR52HSD17B10PTGS1PTGS2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8557848-B2 4,5-ring annulated indole derivatives for treating or preventing of HCV and related viral infections MERCK SHARP & DOHME CORP. (US) 2013-10-15 US disclosed
US-20120078296-A1 BIOMIMETIC COMPOUNDS AND SYNTHETIC METHODS THEREFOR KNC NER ACQUISITION SUB, INC. (US) 2012-03-29 US disclosed
US-20100098661-A1 4,5-RING ANNULATED INDOLE DERIVATIVES FOR TREATING OR PREVENTING OF HCV AND RELATED VIRAL INFECTIONS SCHERING CORPORATION 2010-04-22 US disclosed
WO-1999025713-A1 2-METHOXYIMINO-2-PHENYL ACETAMIDES CONTAINING A KETAL- OR DIALKOXY SUBSTITUTED PYRIDINE MOIETY, THEIR PREPARATION AND THEIR USE AS FUNGICIDES DOW AGROSCIENCES LLC (US) 1999-05-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100098661-A1 4,5-RING ANNULATED INDOLE DERIVATIVES FOR TREATING OR PREVENTING OF HCV AND RELATED VIRAL INFECTIONS ZC3HAV1, IDO1, ZC3HAV1L CYP2A6 92/4885SHBG 901/4885GPR52 2964/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.